Mesenchymal stem cells (MSCs) have an ability to direct the healing process in the face of injury, insult and inflammation. This ability to direct is performed via the secretion of bioactives. Found throughout the body, MSCs are mostly attached to blood vessels of which, fat tissue (adipose) is a plentiful and rich source. From a therapeutic perspective, MSCs have been utilised from self (autologous) and from non-self (allogeneic) for a range of inflammatory and autoimmune conditions. MSCs have the capability to differentiate into specialised cell types like bone, cartilage and muscle to assist with regeneration and repair.
Regeneus is in advanced negotiations for a commercial licensing partnership for Progenza OA in Japan.